A transgender woman is a person who was assigned male at birth but whose gender identity is female. This distinction between assigned sex and experienced gender is the defining feature, and it holds whether or not the person pursues any medical or surgical steps. Research over the past two decades has begun to map the biological, psychological, and social dimensions of being a transgender woman, from structural brain differences detectable before any hormone treatment to the long-term cardiovascular profile of feminizing hormone therapy. The picture that emerges is more layered than most casual accounts suggest.
What Brain Research Shows
One question that comes up repeatedly is whether there is any measurable biological basis for gender identity. Brain imaging studies have started to provide partial answers, though the field is still young. A study of 24 transgender women who had not yet started hormone therapy used a multivariate classifier to estimate where each brain fell on a male-to-female continuum. The brains of the transgender women fell between those of cisgender men and cisgender women, significantly different from both groups, though still closer to the cisgender male end of the spectrum.1PubMed Central. Brain Sex in Transgender Women Is Shifted towards Gender Identity Another imaging study found that treatment-naïve transgender women had lower grey matter volumes in the insula compared to cisgender women, a region involved in body awareness and self-perception.2Scientific Reports. Grey and white matter volumes either in treatment-naïve or hormone-treated transgender women: a voxel-based morphometry study
These findings do not mean there is a single “male brain” or “female brain,” and no scan can diagnose someone as transgender. What the data suggest is that brain anatomy in transgender people is not identical to that of their assigned sex and shows a measurable shift toward their experienced gender. The samples are small, the methods vary, and replication is ongoing. But the direction of the evidence is consistent enough that researchers take it seriously as one piece of a larger puzzle.
Genetics and Biological Factors
Genetics adds another piece, though a modest one. The androgen receptor gene contains a repeating stretch of DNA whose length varies from person to person. Longer repeats are associated with a less sensitive receptor, meaning the body responds less strongly to testosterone. A study comparing transgender women with cisgender male controls found that the transgender women had significantly longer repeat sequences on average.3PubMed Central. Androgen Receptor Repeat Length Polymorphism Associated with Male-to-Female Transsexualism A meta-analysis pooling data from multiple case-control studies confirmed the association, finding that the transgender group had significantly longer repeats overall, though the effect size was small.4The Journal of Sexual Medicine. Polymorphic Cytosine-Adenine-Guanine Repeat Length of Androgen Receptor Gene and Gender Incongruence in Trans Women: A Systematic Review and Meta-Analysis of Case-Control Studies
A small effect size means this gene variant does not determine who is transgender. Many cisgender men carry the same longer repeats, and many transgender women do not. But as one contributing factor among what is likely many, it fits a broader picture in which prenatal hormone exposure and receptor sensitivity shape the development of gender identity in ways that are not yet fully mapped.
What Feminizing Hormone Therapy Does to the Body
Most transgender women who pursue medical transition use feminizing hormone therapy, typically estrogen combined with an anti-androgen. The physical changes unfold over months and years: breast development, redistribution of body fat toward the hips and thighs, softening of skin, and reduced body hair growth. But the effects reach well beyond appearance.
Body composition shifts in a measurable way. Lean mass drops by roughly 3% to 5% in the first year, while fat mass can increase substantially, by as much as 28% in one longitudinal study of 179 transgender women.5PubMed Central. The Impact of Gender-Affirming Hormone Therapy on Physical Performance A separate study found that lean mass indices fell significantly at 12 months while body mass index and visceral fat did not change, and HDL cholesterol (the “good” kind) increased.6PubMed Central. Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women These shifts in muscle and fat have practical implications for strength, athletic performance, and metabolic risk, and they continue to be a subject of research and public debate.
Bone density is one area where hormone therapy appears clearly beneficial. Transgender women frequently have lower bone density than expected even before starting hormones, for reasons that are not fully understood. Estrogen therapy tends to improve those numbers. In one cohort, over 40% of participants had low bone density at baseline; after 12 months of treatment, that figure dropped to about 27%, with a measurable increase in lumbar spine density.7PubMed Central. Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women Short-term trials have not found increased fracture rates.8PubMed Central. Osteoporosis and Bone Health in Transgender Persons
Cardiovascular Risks
Heart and blood vessel health is the area that draws the most medical caution. Estrogen therapy in transgender women appears to raise the risk of blood clots. A large cohort study found that transgender women on hormones had a higher incidence of venous thromboembolism compared to both cisgender men and cisgender women, with the gap widening over time. The differences were more pronounced among those who started hormone therapy during the follow-up period.9PubMed Central. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study
A systematic review and meta-analysis found that stroke incidence in transgender women was about 1.3 times higher than in cisgender men, while venous thromboembolism risk was roughly double. Heart attack risk, by contrast, did not appear elevated.10European Journal of Endocrinology. Cardiovascular disease in transgender people: a systematic review and meta-analysis A narrative review of the broader literature reached a similar conclusion: estrogen likely increases the risk of cardiovascular events in transgender women, though the exact magnitude remains uncertain.11PubMed Central. Cardiovascular Risk in Transgender People With Gender-Affirming Hormone Treatment Clinicians generally recommend managing standard risk factors like smoking, blood pressure, and cholesterol proactively, especially as patients age on long-term estrogen therapy.12PubMed. Transgender health and the impact of aging and menopause
Mental Health and Hormone Therapy
The mental health benefits of hormone therapy are among the most consistently reported findings in the field. A systematic review of multiple prospective studies found that depressive symptoms dropped across every study that measured them, with one cohort showing the proportion of participants with symptoms of depression falling from 42% to 22% over 12 months. No study in the review found that hormone therapy increased depression.13PubMed Central. Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review A separate systematic review found that gender-affirming hormone therapy consistently reduced depressive symptoms and psychological distress.14Nature Human Behaviour. A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people A more recent study comparing transgender adults prescribed hormone therapy with those who were not found that the treated group had about a 15% lower risk of moderate-to-severe depressive symptoms.15JAMA Network Open. Gender-Affirming Hormone Therapy and Depressive Symptoms Among Transgender Adults
That said, reviews have noted that the overall strength of evidence is limited by small sample sizes, lack of control groups, and difficulty separating the effects of hormones from the effects of social transition, therapy, and other life changes happening simultaneously. The direction of the evidence is clear; the precision of the effect is not.
Separate from the direct effects of hormones, transgender women face elevated rates of depression and anxiety linked to stigma, discrimination, and social rejection. Research has documented how these experiences of minority stress contribute to health disparities, including higher rates of depression compared with the general population.16PubMed Central. Measuring Experiences of Minority Stress for Transgender Women: Adaptation and Evaluation of Internalized and Anticipated Transgender Stigma Scales One study of transgender women in China found that discrimination, victimization, and life dissatisfaction were all significantly associated with riskier health behaviors, illustrating how external stressors translate into concrete health outcomes.17PubMed. Impact of Minority Stress and Poor Mental Health on Sexual Risk Behaviors among Transgender Women Sex Workers in Shenyang, China
Voice Training and Surgical Options for Voice
Estrogen therapy does not reverse the vocal changes caused by testosterone-driven puberty. The vocal folds, once thickened, stay that way. Transgender women who want a higher-pitched, more typically feminine voice generally pursue speech therapy, surgery, or both.
Voice training with a speech-language pathologist works on raising pitch, adjusting resonance, and changing speech patterns like intonation and phrasing. A randomized controlled trial found that a combination of pitch elevation therapy and articulation training raised the fundamental frequency by about 49 Hz during sustained vowels and reading, and by about 29 Hz during spontaneous speech.18PubMed. Short-Term Acoustic Effects of Speech Therapy in Transgender Women: A Randomized Controlled Trial A separate study found that the gains held at extended follow-up, with average pitch increasing by about 65 Hz on sustained vowels and vocal satisfaction continuing to improve after training ended.19PubMed. Patient Satisfaction and Acoustic Changes in Trans Women after Gender Affirming Voice Training Another study found that two-thirds of participants increased their vocal satisfaction to a meaningful degree, and all were rated as more female-sounding by listeners after training, though not all to a degree that would be perceived as clearly feminine.20PubMed. Gender-Affirming Voice Training for Trans Women: Effectiveness of Training on Patient-Reported Outcomes and Listener Perceptions of Voice
For those who want a more permanent change or find training insufficient, glottoplasty is a surgical procedure that shortens the vibrating length of the vocal folds, raising resting pitch. One study reported a mean increase in speaking pitch of about 25 Hz and a large improvement in voice-related quality of life, with self-perceived femininity jumping from about 3 out of 10 before surgery to nearly 8 out of 10 afterward.21PubMed Central. Effect of Wendler glottoplasty on voice and quality of life of transgender women The tradeoffs are real, though: glottoplasty tends to reduce vocal range and speaking volume on a long-term basis, and complications like granulomas, suture separation, and persistent breathiness are not uncommon.22PubMed. Complications and Functional Voice Limitations Following Gender-Affirming Laryngeal Surgery (GALS) The voice tends to improve progressively over the months following surgery, with quality and range partially recovering over time.23PubMed. Voice Outcome of Glottoplasty in Trans Women
Surgical Transition and Satisfaction
Gender-affirming surgeries for transgender women span a wide range, but two of the most discussed are vaginoplasty and facial feminization surgery.
Vaginoplasty, most commonly performed using penile inversion technique, creates a functional neovagina. A study of surgical outcomes found that about 82% of patients reported the ability to orgasm after surgery, about 70% rated their postoperative self-confidence above 7 out of 10, and 93% said they would choose to have the surgery again.24PubMed. Impact of vaginoplasty on sexual health and satisfaction in transgender women
Facial feminization surgery encompasses a group of procedures targeting bone structure and soft tissue of the face, commonly including forehead recontouring, rhinoplasty, jawline reshaping, and chin work. A systematic review found that about 90% of patients reported being “satisfied” or higher with their outcome.25PubMed Central. Facial Feminization Surgery: A Systematic Review of Perioperative Surgical Planning and Outcomes A study using a validated facial satisfaction questionnaire found that jawline satisfaction showed the greatest increase, followed by the nose, and that both psychological and physical quality of life improved significantly.26PubMed Central. Quantifying Facial Feminization Surgery’s Impact: Focus on Patient Facial Satisfaction Hair removal, typically with laser or electrolysis, is another common step in physical transition and often required before genital surgery to prevent hair growth inside the neovagina.27Dermatologic Surgery. A Review of Best Practices for Gender-Affirming Laser Hair Removal
The Neovaginal Microbiome
The microbiome of a surgically created neovagina is an area of active research and one that matters for long-term gynecological care. Unlike a cisgender vagina, which is typically dominated by Lactobacillus bacteria, a penile-inversion neovagina harbors a much more diverse bacterial community. The most common bacteria found in neovaginas include Porphyromonas, Peptostreptococcus, and Prevotella, and the overall microbial diversity is significantly higher than in cisgender vaginas.28PubMed Central. The neovaginal microbiome of transgender women post-gender reassignment surgery A systematic review found that penile-inversion neovaginas most closely resembled cisgender vaginas with bacterial vaginosis, while neovaginas created from intestinal tissue had microbiomes more like the colon.29PubMed Central. The microbiome of the neovagina: a systematic review and comparison of surgical techniques
A more recent study characterized four distinct bacterial clusters in neovaginas, each with a different immune profile. One cluster was associated with low inflammation and appeared stable over time, while another was linked to higher levels of inflammatory markers. Lactobacillus was detectable in some participants, but Lactobacillus-dominant communities were rare.30PubMed Central. The neovaginal microbiota, symptoms, and local immune correlates in transfeminine individuals with penile inversion vaginoplasty These findings mean that standard gynecological guidance designed around a Lactobacillus-dominated environment does not always apply. Clinicians caring for transgender women after vaginoplasty are working with a different baseline, and screening recommendations are still catching up.
Fertility Preservation
Feminizing hormones suppress sperm production, and the longer someone is on therapy, the more pronounced the effect becomes. In one comparison, transgender women who had cryopreserved sperm before starting hormones had a mean motile sperm count of about 63 million, while those who stopped hormones for three to six months before banking had about 39 million. Those who continued hormones during banking had counts near zero.31PubMed Central. Fertility Preservation and Reproductive Potential in Transgender and Gender Fluid Population
Even before any hormone treatment, though, transgender women tend to have lower semen quality than the general population. A large study of cryopreserved samples collected before gender-affirming treatment found that sperm volume, concentration, count, and motility were all significantly below standard reference values. Only about a quarter of post-thaw samples were adequate for intrauterine insemination; another 13% were suitable for standard IVF, and the majority would require more advanced reproductive techniques.32Human Reproduction. Impaired semen quality in trans women: prevalence and determinants A prospective cohort study confirmed that even among participants who had never taken hormones, sperm abnormalities were more common than expected.33PubMed. Sperm quality in transgender women before or after gender affirming hormone therapy-A prospective cohort study The reasons for this pre-treatment impairment are not well understood and may involve lifestyle factors, stress, or unknown biological contributors.
Breast Cancer Screening
Breast tissue develops under estrogen therapy, and with that tissue comes a cancer risk that falls somewhere between the risk for cisgender men and cisgender women. Transgender women on long-term hormone therapy develop breast cancer at a higher rate than cisgender men but at a much lower rate than cisgender women.34PubMed Central. Contemporary Considerations for Breast Cancer Risk and Screening in Transgender, Nonbinary, and Gender-Diverse Populations Current recommendations are still evolving, but many clinicians suggest that transgender women who have been on estrogen for five or more years consider breast cancer screening following the same guidelines that apply to cisgender women.
Drug Interactions With Hormone Therapy
An underappreciated dimension of transgender healthcare is how feminizing hormones interact with other medications. This matters especially for transgender women living with HIV, since antiretroviral drugs and estrogen are metabolized through overlapping pathways. Older antiretrovirals like efavirenz have been found to lower estradiol levels, which could undermine the effectiveness of hormone therapy.35PubMed Central. Drug-Drug Interactions in Transgender Patients Receiving Antiretroviral and Hormonal Therapy: A Systematic Review of Clinical Studies and Reports Newer drugs appear more compatible. A randomized crossover trial found that the antiretroviral combination of doravirine and tenofovir did not meaningfully alter estradiol levels, and the hormones did not significantly affect antiretroviral drug levels either.36PubMed Central. Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial
Psychiatric medications also warrant attention. Among transgender adults taking both hormone therapy and psychiatric drugs, about a third of those on multiple psychiatric medications had a potential drug-hormone interaction, compared to about 7% of those on a single psychiatric medication.37PubMed Central. Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy These interactions do not always cause clinical problems, but they underscore the importance of having a provider who is aware of all medications a patient is taking and can monitor hormone levels accordingly.
Aging and Healthcare Barriers
As the first generation of transgender women to access hormone therapy in significant numbers moves into middle and older age, long-term health monitoring is becoming increasingly important. A systematic review of aging in transgender people found that older transgender individuals were significantly less likely than cisgender peers to undergo routine preventive screenings. The odds of getting a colonoscopy, mammogram, osteoporosis test, or even a basic physical exam were all substantially lower.38PubMed Central. Getting old in the desired gender: a systematic review on aging diseases in transgender people The reasons are complex: distrust of healthcare systems, fear of discrimination, confusion about which screenings apply, and sometimes provider uncertainty about how to care for aging transgender patients.
The electronic health record itself can be a source of harm. A qualitative study found that wrong names, pronouns, and gender markers in medical records were common, eroding trust and sometimes causing patients to avoid care entirely. Clinicians’ notes sometimes contained stigmatizing language, and the limitations of health record systems created barriers to appropriate care, such as flagging screenings that did not apply or failing to flag ones that did.39PubMed Central. Experiences of Transgender People Reviewing Their Electronic Health Records, a Qualitative Study Another study found that sensitive gender identity information had been involuntarily disclosed or mishandled for virtually all participants, compromising both safety and willingness to seek care.40PubMed Central. Patient Perspectives on Gender Identity Data Collection in Electronic Health Records: An Analysis of Disclosure, Privacy, and Access to Care
Adolescent Transition and Growth
For transgender girls who begin medical intervention before or during puberty, the trajectory looks different from that of adults. Puberty blockers (GnRH agonists) can pause testosterone-driven development, and later addition of estrogen induces a feminizing puberty. A study of Danish transgender adolescents found that most trans girls treated with this approach reached an adult height within the reference range for cisgender girls. A growth spurt was observed during estradiol therapy, but adult height tended to be about 2.7 centimeters shorter than predicted based on parental heights.41The Journal of Clinical Endocrinology & Metabolism. Growth and Adult Height Attainment in Danish Transgender Adolescents Treated With GnRH Analog and Sex Hormones Adolescent transition avoids some of the irreversible effects of testosterone puberty, such as voice deepening, facial bone growth, and height gain beyond female norms, but it also raises questions about long-term fertility, bone density trajectories, and decision-making capacity that remain subjects of active research and debate.